H3 Biomedicine Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:H3 Biomedicine Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014197
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
H3 Biomedicine Inc (H3 Biomedicine), a subsidiary of Eisai Co Ltd is a biopharmaceutical company that offers therapies. The company concentrates on discovery and early development of novel, targeted anti-cancer compounds. Its products include small-molecule drugs that are developed by utilizing synthetic chemistry approaches and advanced cell-based screening methods. H3 Biomedicine concentrates on scientific approaches and develops new platforms for multiple drug candidate programs. The company leverages the external and internal cumulative investment in cancer genomics to identify therapeutic targets and biomarkers. It operates in the areas of genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry. The company operates through other biotechnology companies for research and development activities and advance cancer treatment options. H3 Biomedicine is headquartered in Cambridge, Massachusetts, the US.

H3 Biomedicine Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
H3 Biomedicine Inc, Medical Devices Deals, 2011 to YTD 2017 9
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cancer Genetics Partners with H3 Biomedicine 11
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 12
H3 Biomedicine Extends Agreement with Selvita 13
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 14
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 15
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 16
Licensing Agreements 17
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 17
H3 Biomedicine Inc – Key Competitors 18
H3 Biomedicine Inc – Key Employees 19
H3 Biomedicine Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Feb 20, 2017: H3 Biomedicine Announces Appointment of Peter G. Smith, Ph. D., to Chief Scientific Officer 21
Jun 01, 2016: H3 Biomedicine Announces Appointment of Tarek Sahmoud as Chief Medical Officer 22
Product News 23
03/09/2017: H3 Biomedicine to Present on H3B-6545 at 2017 American Association of Cancer Research Annual Meeting 23
Product Approvals 24
May 11, 2016: H3 Biomedicine Receives FDA Acceptance for Investigational New Drug Application 24
Clinical Trials 25
Jul 24, 2017: H3 Biomedicine and University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Key Facts 2
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
H3 Biomedicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
H3 Biomedicine Inc, Deals By Therapy Area, 2011 to YTD 2017 8
H3 Biomedicine Inc, Medical Devices Deals, 2011 to YTD 2017 9
H3 Biomedicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cancer Genetics Partners with H3 Biomedicine 11
Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 12
H3 Biomedicine Extends Agreement with Selvita 13
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 14
H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 15
Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 16
Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 17
H3 Biomedicine Inc, Key Competitors 18
H3 Biomedicine Inc, Key Employees 19

★海外企業調査レポート[H3 Biomedicine Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sears Holdings Corporation (SHLD):企業の財務・戦略的SWOT分析
    Sears Holdings Corporation (SHLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • First Solar Inc (FSLR):企業の財務・戦略的SWOT分析
    First Solar Inc (FSLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Mitsubishi Heavy Industries, Ltd.:戦略・SWOT・企業財務分析
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Tieto Corporation:企業のM&A・事業提携・投資動向
    Tieto Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tieto Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Unichem Laboratories Ltd (UNICHEMLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Unichem Laboratories Ltd (Unichem) is an integrated, specialty pharmaceutical company which manufactures pharmaceutical formulations, generic products and active pharmaceutical ingredients (API's). The company offers its products in the therapeutic areas of gastroenterology, anti-invectives, …
  • Lexicon Pharmaceuticals Inc (LXRX):企業の財務・戦略的SWOT分析
    Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Hyundai Engineering & Construction Co Ltd (000720):電力:M&Aディール及び事業提携情報
    Summary Hyundai Engineering & Construction Co Ltd (Hyundai E&C), a subsidiary of Hyundai Motor Co, is an engineering and construction contracting company. It provides civil and construction works for roads, bridges, harbors, highways and railways. It also undertakes property development of residenti …
  • Kalle GmbH:企業の戦略的SWOT分析
    Kalle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Bank of Shanghai Co., Ltd.:企業の戦略・SWOT・財務情報
    Bank of Shanghai Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Shanghai Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Pioneer Corporation:企業の戦略・SWOT・財務分析
    Pioneer Corporation - Strategy, SWOT and Corporate Finance Report Summary Pioneer Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • IMCD N.V.:企業のM&A・事業提携・投資動向
    IMCD N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IMCD N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Chevron Corp (CVX):電力:M&Aディール及び事業提携情報
    Summary Chevron Corp (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for, produces and transports crude oi …
  • PowerFilm, Inc.:企業の戦略的SWOT分析
    PowerFilm, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Ocean Power Technologies Inc (OPTT):電力:M&Aディール及び事業提携情報
    Summary Ocean Power Technologies, Inc. (OPT) is a provider of ocean energy solutions. The company harnesses the abundant wave power to draw out renewable energy; and commercializes ocean wave power conversion technology products. The company's PB3 PowerBuoy integrates patented technologies in hydrod …
  • Autoliv Inc (ALV):企業の財務・戦略的SWOT分析
    Autoliv Inc (ALV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vivartia Holdings SA.:戦略・SWOT・企業財務分析
    Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report Summary Vivartia Holdings SA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Triumvira Immunologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Triumvira Immunologics Inc (Triumvira) is a biopharmaceutical company developing engineered T cell therapies for the treatment of multiple cancers. Its proprietary immuno-oncology platform T cell Antigen Coupler (TAC), enables natural T cell receptor to induce a controlled, tumor-specific re …
  • Daechang Forging Co Ltd
    Daechang Forging Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daechang Forging Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Grupa Azoty SA (ATT):企業の財務・戦略的SWOT分析
    Grupa Azoty SA (ATT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Insys Therapeutics Inc (INSY)-製薬・医療分野:企業M&A・提携分析
    Summary Insys Therapeutics Inc (Insys) is a specialty pharmaceutical company, which discovers, develops and commercializes novel drug delivery systems. The company’s flagship product, Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients. Its lead prod …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆